Investor Presentation: First Nine Months of 2020
22
Investor presentation
First nine months of 2020
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Diabetes care
DKK
billion
700
600
500
400
300
200
CAGR¹ value: 12.0%
100
0
Aug
2015
Obesity care
DKK
billion
#1
50%
12
10
40%
8
30%
Haemophilia
DKK
billion
#1
80%
80
60%
00
60
40%
40
40
Novo NordiskⓇ
(#2
50%
40%
30%
20%
20%
4
20%
20
10%
2
CAGR² value: 10.1%
CAGR³ value: 2.0%
10%
0%
0
0%
0
0%
Aug
2020
Aug
Aug
FY
FY
2018
Market value
2020
2015
Market value
2019
-NN value market share
-NN value market share
Global market position
Global market position
Market value
NN value market share
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 5-year period; Note: Annual sales figures for haemophilia A, B and bypassing agents segment. Recombinant and plasma derived products
Source: Company reports, IQVIA MAT, Aug 2020
NN: Novo NordiskView entire presentation